FDA Repeats Birth-Defect Risk With Roche, Novartis Transplant Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
PML could be a hazard, too, agency says.
You may also be interested in...
REMS Strength Driven More By Drug’s Benefits Than Risks, FDA Suggests
FDA is unwilling to subject organ transplant patients to the delays caused by requiring prescriber and pharmacy certification, and so the REMS requirements for mycophenolate products are less strict than for other, less critical teratogenic drugs.
CellCept, Myfortic Labeling Get PML Warning
Labeling update for transplant drugs follows postmarketing reports of progressive multifocal leukoencephalopathy.
CellCept, Myfortic Labeling Get PML Warning
Labeling update for transplant drugs follows postmarketing reports of progressive multifocal leukoencephalopathy.